All In Biotech

Drug Trial Radar · NCT05307328

SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome

Last checked: Nov 19, 2026Latest source record: Oct 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

26

Actual

Start

Sep 1, 2022

Primary completion

Aug 1, 2025

Study completion Aug 1, 2025

Sponsor

Lead sponsor
Sparrow PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Apr 1, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, placebo-controlled, study of SPI-62 in subjects with ACTH-dependent Cushing's syndrome caused by a non-adrenal tumor. Subjects will receive each of the following 2 treatments for 24 weeks: SPI-62 and matching placebo with the option of long-term extension.

Conditions

  • Cushing's Syndrome I
  • Cushing Disease Due to Increased ACTH Secretion
  • Cortisol Excess
  • Cortisol; Hypersecretion
  • Cortisol Overproduction
  • Ectopic ACTH Secretion

Interventions

  • SPI-62Drug

    11β hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor

  • PlaceboDrug

    Inactive tablets identical to SPI-62 tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in urinary HSD-1 ratioTime frame: Baseline to 6 weeks

Locations

12 sites in 3 countries. Site status is shown where the registry gives one.

  • St. Joseph's Hospital and Medical Center - Barrow Neurological Institute (BNI) - Pituitary Center

    Phoenix, Arizona

  • Southwest General Healthcare Center

    Fort Myers, Florida

  • Mayo Clinic Cancer Center (MCCC) - Rochester

    Rochester, Minnesota

  • Washington University School of Medicine - Center for Advanced Medicine (CAM)

    St Louis, Missouri

  • Comprehensive and Interventional Pain Management Llp

    Henderson, Nevada

  • Memorial Sloan-Kettering Cancer Center

    New York, New York

  • Oregon Health & Science University (OHSU) - Northwest Pituitary Center

    Portland, Oregon

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania

  • Medical University of Plovdiv

    Plovdiv, Bulgaria

  • Clinical Center of Endocrinology and Gerontology, University Hospital of Endocrinology, Medical University Sofia (USHATE)

    Sofia, Bulgaria

  • Medical University of Sofia

    Sofia, Bulgaria

  • Carol Davila University of Medicine and Pharmacy

    Bucharest, Romania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.